The much-awaited tagging of the price of Bristol-Myers Squibb’s PD-1 hero Opdivo in China was finally revealed by the company to be half of its cost in the U.S.

A local news network reported that the selling price of the 100mg/10ml vial of the medicine is slated to be 9,260 Yuan ($1,354) and that of the 40mg/4ml dose to be 4,591 Yuan ($671). As mentioned on the website GoodRx. The bigger vial is priced from $2,600 to $2,800, and the smaller vial is priced around $1,100 in the United States.

This price has not been validated by the Bristol-Myers Squibb spokeswoman and few reports suggest that the firm is “working with the government to complete” the costing procedure.

“The price of Opdivo will take the value of the medicine, affordability for Chinese patients and the high unmet medical needs into consideration,” the pharma company mentioned in a statement. In order to make Opdivo available to larger populations, the company aims to collaborate with buyers and third parties via different schemes.

The dose is calculated to be administered as 3mg/1 kg of body weight every fortnight. This totals the expense for the medication to be 18,442 Yuan per fortnight to a patient who weighs 60 kg. However, after offering this significant cut in price, the price is unaffordable for patients in China.

Opdivo, if incorporated in insurance schemes powered by the government, could be sold at even lower prices. The head of Opdivo’s Chinese-specific phase 3 trial resulting in its sanction, Professor Yilong Wu comments that he does not feel that Opdivo’s inclusion for the cost wavering is possible.